Dr Peter Black - Vancouver Prostate Centre, Canada
Dr. Peter Black is a Urologic Oncologist at Vancouver General Hospital, a Research Scientist at the Vancouver Prostate Centre, and an Associate Professor in the Department of Urologic Sciences at the University of British Columbia (UBC). He received his undergraduate degree from UBC and his medical degree from Johannes Gutenberg University in Mainz, Germany. He completed his urologic training at the University of Washington in Seattle and fellowship in urologic oncology at M.D. Anderson Cancer Center in Houston, Texas.
Dr. Black has a clinical subspecialty interest in bladder and prostate cancer. His grant-funded translational research program focuses primarily on molecular biomarkers and targeted therapies in urothelial carcinoma. His recent work has identified genomic signatures that predict outcome after neoadjuvant chemotherapy in muscle-invasive bladder cancer, and these have recently been commercialized. He is an active clinical trialist and is currently principle investigator of a co-operative group (SWOG) trial testing atezolizumab in BCG-unresponsive non-muscle invasive bladder cancer.
Dr Paul Boutros - Ontario Institute for Cancer Research, Canada
Dr. Paul Boutros received his undergraduate training in Chemistry and his graduate work in Medical Biophysics. He then became a Principal Investigator in Informatics & Biocomputing at the Ontario Institute for Cancer Research, and an Associate Professor at the University of Toronto. Dr. Boutros’ research develops machine-learning and other computational techniques that are applied to large cohorts of genomic and radiologic cancer data to develop novel diagnostic, prognostic and predictive biomarkers. Dr. Boutros co-leads the Canadian Prostate Cancer Genome Network, and has received the University of Waterloo Young Alumni Award and the University of Toronto Graduate Teaching Award.
Dr William Catalona - Northwestern University Feinberg School of Medicine, Northwestern University, United States
Dr. Catalona joined the Northwestern faculty in 2003. He is known for having been the first to show that a simple blood test that measures levels of prostate-specific antigen (PSA) is the most accurate method for detecting prostate cancer and for having developed the “free” PSA test as a means of improving the accuracy of prostate cancer screening.
Dr. Catalona is currently conducting research into the genetics of prostate cancer which could lead to new tests for the disease as well as possible new means of treating or preventing prostate cancer. He specializes in prostate cancer surgery and is recognized as an expert in performing the “nerve-sparing” radical prostatectomy that can preserve sexual potency.
In addition to his appointment as Professor of Urology, Dr. Catalona also serves as Director of the Clinical Prostate Cancer Program of Northwestern’s Robert H. Lurie Comprehensive Cancer Center.
Mr Ben Challacombe - Guy’s and St Thomas Hospitals NHS Foundation Trust, King’s College London, United Kingdom
Consultant Urological Surgeon and Honorary Senior Lecturer with a special interest in robotic surgery and minimally invasive prostate cancer treatments. Ben is associate editor of the BJUI, with over 140 peer-reviewed publications and 20 book chapters on minimally invasive and robotic urological techniques. He has performed over 400 robotic radical prostatectomies, 160 robotic partial nephrectomies and also performs dynamic prostate brachytherapy and holmium laser prostatectomy (HoLEP) within the Guy’s Urology Centre.His current research interests are in robotic surgery training, trans-perineal template biopsy techniques, active surveillance of low risk prostate cancer, sentinel lymph node techniques and haptic probe development in robotic surgery.
Dr Brian Chapin MD - Anderson Cancer Centre, United States
Dr. Brian Chapin is an Assistant Professor in the Department of Urology at The University of Texas MD Anderson Cancer Center. He provides complete surgical care for men and women diagnosed with urologic malignancies. He performs open surgery and minimally invasive/robotic surgery, for patients with prostate, kidney, bladder and testis cancers. His major clinical focus is on the treatment of high risk- localized, locally advanced and metastatic prostate cancers. He has active clinical research protocols developing the integration of surgical, radiation and medical therapies in the treatment of advanced prostate cancer. Dr. Chapin is involved with the basic science/translational research program at M.D Anderson, which is attempting to identify the immunologic changes that occur with surgical and systemic therapy treatments in advanced prostate cancer and how these changes may be exploited with use of newer immune modulating therapies. Using a comprehensive multimodality approach to this disease, Dr. Chapin’s goal is to ease suffering and prolong survival in men with advanced prostate cancer.
Prof Mark Emberton - University College London Hospitals, United Kingdom
Mark Emberton’s principal interests lie in trying to improve diagnostic and therapeutic pathways for men with prostate cancer, principally through the use of novel imaging techniques and minimally-invasive treatments. He is the principal investigator in a number of studies in this area. Mark Emberton and his team of researchers have initiated a clinical innovation programme exploring the role of focal therapy in men with prostate cancer. This involves treating only the areas of prostate cancer rather than the whole gland.
Dr Jonathan Epstein - Johns Hopkins Medical Institutions, United States of America
Dr. Jonathan I. Epstein is a Professor of Pathology, Oncology and Urology at the Johns Hopkins School of Medicine. He also serves as the Director of Surgical Pathology at The Johns Hopkins Hospital. He is recognized as a leader in the field of urological pathology.
Dr. Epstein completed a combined liberal arts and medical degree program at Boston University, receiving both B.A. and M.D. degrees. He obtained his residency training in anatomic pathology at The Johns Hopkins Hospital, followed by a fellowship in oncological pathology at the Memorial Sloan-Kettering Cancer Center in New York. He has been on the faculty at Johns Hopkins since 1985.
Dr. Epstein lectures widely in the United States and overseas on urological pathology, with emphasis on prostatic and bladder disease, and has written 7 books and more than 800 articles. Among many awards, he has been honored with the Koss Medal for Advancement of Urological Pathology, the Arthur Purdy Stout Surgical Pathology Prize and the American Cancer Society Clinical Oncology Career Development Award.
Dr. Epstein has one of the largest surgical pathology consulting services in the world with approximately 12,000 cases per year, covering the full range of urologic pathology. Dr Epstein uses these consultations to train 4 genitourinary pathology fellows each year, the largest genitourinary pathology fellowship in the world.
He is a member of the American Urologic Association, the Arthur Purdy Stout Society of Surgical Pathologists and the International Society of Urologic Pathology. He holds editorial appointments to 11 medical journals, including American Journal of Surgical Pathology, Urology, and Human Pathology.
Prof Nicholas James BSc (First Class Honours) MBBS PhD FRCP FRCR - University of Birmingham and Queen Elizabeth Hospital, United Kingdom
Proudly Sponsored by
Professor James is Consultant Clinical Oncology at the Queen Elizabeth Hospital Birmingham and Honorary Professor of Clinical Oncology at the University of Birmingham. He qualified in 1983 from St Bartholomew’s with the principal class medical prize and a First in Immunology. He undertook postgraduate medical training in London, Brussels and Tokyo together with a PhD at Imperial College London. He has been based in Birmingham since 1994.
Prof James is internationally renowned for his work in Urological Cancer. He is a regular educational speaker at conferences worldwide, recently including the American Society of Clinical Oncology, European Society of Medical Oncology and European Association of Urologists Annual Meetings.
In the bladder cancer field he has lead trials programme of chemotherapy and radiotherapy. This has encompassed phase 1 to 3 studies of bladder preservation with combined radiotherapy and low toxicity chemotherapy. This culminated in the BC2001 trial, the largest ever study of bladder preservation, which showed a 40% gain in pelvic control rates. The New England Journal of Medicine Described the results as a ‘landmark’ and ‘practice changing’.
In prostate cancer he is chief investigator for the international, multi-centre STAMPEDE trial. This study has developed a novel structure to assess multiple research questions and is the largest prostate cancer study (>9000 men). His 2016 Lancet paper on the STAMPEDE results showed a 25% survival gain with upfront docetaxel, the first major change in care for newly diagnosed advanced prostate cancer since 1941.This led to a Rapid Evidence Review by the UK National Institute for Health and Clinical Excellence (NICE) and a rare revision of prostate cancer commissioning ‘in year’ by the National Health Service in England to fast-track the ground breaking results of the STAMPDE trial. Further survival data from STAMPEDE with abiraterone were published in the New England Journal of Medicine and presented at the American Society of Clinical Oncology, European Society of Medical Oncology Annual Meeting. These show that the 1st in line use of abiraterone prolongs survival by 37% with a gain in failure free survival of 80%. These data are expected to be practice changing.
Both the STAMPEDE and BC2001 outcomes have underpinned changes to guidelines published by NICE, the European Urology Association, European Society of Medical Oncology and American Society of Clinical oncology.
Outside the clinical and research spheres, Prof James is closely engaged with patient education initiatives. This is best exemplified by a series of music concerts, in collaboration with the world famous saxophonist Courtney Pine, entitled ‘It’s a Man Thing’. These concerts have been used to disseminate information about prostate cancer and in particular the four-fold excess risk of death from the disease in men of Afro-Caribbean origin. He also co-founded the leading website CancerHelp UK in 1994. The website was one of the first to focus exclusively on patient information and was underpinned by a programme of education research. It featured the first searchable database of clinical trials for patients seeking to enter a study. In 2002 it became the main patient resource on the Cancer Research UK website.
Dr Herbert Lepor - NYU Langone Medical Center, United States
I was six years old when open heart surgery saved my brother’s life. It was the first of many times when I thought about becoming a doctor, so that I, too, could save someone’s life. For more than 26 years, I’ve had that opportunity. I’ve treated more than 5,000 patients who’ve had prostate cancer and are now thriving after having their prostate gland removed through radical prostatectomy.
I came to NYU Langone in 1993, because I had a tremendous opportunity to build a world-class urology department here. Since then, our department has defined state-of-the-art care by improving outcomes for radical prostatectomy. For example, we now use a technique that spares the nerves, preserving function as much as possible.
We have also pioneered the use of MRI to diagnose and pinpoint the precise location of prostate cancer. More than 90 percent of patients who’ve needed surgery to remove the prostate at NYU Langone have reported long-term satisfaction with the outcomes.
We are at the forefront of research into prostate cancer, using image-guided diagnostic techniques, such as MRI, to help us determine the best treatment—whether it’s surveillance of slow-growing cancer, the need for complete removal of the prostate, or destroying one malignant area without using surgery.
It’s the connection we make with patients and their families that humanizes medicine in this age of technology. For this reason, I take the time to listen to my patients and guide them through treatment, every step of the way.
Dr Max (Massimo) Loda - Dana-Farber Cancer Institute, United States
Massimo Loda, MD is a Professor of Pathology, a senior Staff Pathologist at Brigham and Women’s Hospital, Chair of Dana-Farber Cancer Institute’s Department of Oncologic Pathology, principal investigator on an RO1 focused on the connection between metabolic syndrome and aggressive prostate cancer. Core Director of Pathology Cores in the Prostate, Pancreas and GI Cancer SPORES and program projects. Dr Loda’s laboratory has been focused for several years in the study of biomarkers of cancer pathogenesis and progression (with specific interest in prostate and GI cancers) as well as metabolic alterations either associated with ongogene activation or as primary drivers of tumororigenesis.
Professor Thomas H Lynch - St. James’s Hospital and Trinity College, Dublin
Professor Thomas Lynch is a consultant urological surgeon at St.James’s Hospital and Trinity College, Dublin. In addition to his special interest in urological oncology he is the lead urologist in laboratory-based prostate cancer research with multiple publications in this area. He has an extensive training in urological oncology in the US, the UK and Ireland.
He has a track record as an innovator, academic and teacher and has lectured and published extensively on prostate cancer and has always been involved in new innovations in patient care. He has been heavily involved in the development of national guidelines for prostate cancer diagnosis and chaired the expert group for the Health Service Executive (HSE) in Ireland. He was also a member of the expert group for the much-acclaimed Irish Health Technology Assessment for Health Information and Quality Authority (HIQA) on robotic surgery.
He has won several grant bids for research and clinical funding. He has also won several awards including The British Journal of Urology International Award, The British Association of Urological Surgeons
(BAUS) Prize and The International Association of Radiation Research Prize. He is a reviewer for several peer-review journals.
Dr Christian Nelson - Memorial Sloan Kettering Cancer Centre, United States
I am a clinical psychologist with expertise in treating men with prostate cancer and other genitourinary malignancies. As the psychological liaison to Memorial Sloan Kettering’s genitourinary and sexual medicine services, I provide short- and long-term counseling services to patients struggling with cancer-related issues. Men who are undergoing treatment for these diseases sometimes experience treatment-related sexual dysfunction, and I help them and their partners optimize intimacy before, during, and after treatment. I also work with the Center’s 65+ Program, providing psychological support for our patients who are 65 and older, and I co-facilitate a support group for patients dealing with the combined issues of cancer and aging.
Dr John Oliffe - University of British Columbia, Canada
Dr. John Oliffe is a Professor and Associate Director Research at the School of Nursing, University of British Columbia and the founder and lead of UBC’s Men’s Health Research program (www.menshealthresearch.ubc.ca ). His research is focused on gender and men’s health addressing how masculinities influence men’s health behaviors and illness management, and its impact on partners, families and overall life quality. His research studies address diverse topics including prostate cancer, depression, suicide and smoking cessation.
Prof Piet Ost - CRIG, Belgium
Adj Head of clinic – Radiation oncology (UZ Gent)
Assistant professor (Faculty of Medicine and Health Sciences, UGent)
Member of the Steering Committee of ION (immuno-oncology network) Ghent
Vice-chairman of the Young Academic Urologist Prostate Cancer Working group of the EAU.
Prof leads his team focusing on urothelial cancers with a strong research focus on prostate cancer. In this field they have followed and implemented new technologies such as IMRT, SBRT, VMAT as well as new systemic treatments such as abiraterone, enzalutamide,… Another important focus is the implementation of new diagnostic tools in the re-staging of prostate cancer and implementation of metastasis-directed therapy for prostate cancer with limited metastases (oligometastases).
A recent interest in this field is the development of prognostic or predictive circulating biomarker panels for which collaboration with several other departments has been established inside and outside Ugent.
A second interest is immunotherapy and the implementation of new agents (anti-CTLA4, anti-pd-(l)1,…) into the clinic with or without radiotherapy. He is leading several ongoing fase I/II trials of immunotherapy in melanoma, bladder cancer and renal cell carcinoma.
Dr David Penson - Vanderbilt University Medical Center, United States
David F. Penson, MD, MPH is the Paul V. Hamilton, M.D. and Virginia E. Howd Chair in Urologic Oncology, Director of the Center for Surgical Quality and Outcomes Research and Professor and Chair, Department of Urologic Surgery at Vanderbilt University. He currently maintains a clinical practice in urologic oncology at the Vanderbilt-Ingram Cancer Center. His specific research foci include the comparative effectiveness of treatment options in localized prostate cancer and the impact of the disease and its treatment on patients’ quality of life. He also maintains a keen interest in health policy and improving the quality of healthcare both in the US and worldwide.
Dr Cora Sternberg - Samuel & Barbara Sternberg Foundation - ONLUS, Italy
Dr. Cora N. Sternberg is Chief of the Department of Medical Oncology at the San Camillo Forlanini Hospital in Rome, Italy and Adjunct Professor at La Sapienza University in Rome. She is also Adjunct Professor of Urology and Urological Oncology at Tufts University School of Medicine and the Lahey Clinic in Boston, Massachusetts, USA, and Adjunct Professor at Temple University’s College of Science and Technology in Philadelphia, Pennsylvania.
Dr. Sternberg has served as Coordinator for Genitourinary Oncology Education for the European Society for Medical Oncology (ESMO) and as the Genitourinary Oncology Program Chairman for the European CanCer Organisation (ECCO). She was an elected Board Member and Treasurer of the European Organization for Research and Treatment of Cancer (EORTC) for three terms and was on the Executive Committee as treasurer of the EORTC. Dr. Sternberg was the 2nd Scientific Chairman of the ASCO Prostate/Genitourinary Cancer Symposium Program Committee and was then the ASCO Steering Committee Chairman. Dr. Sternberg was the scientific co-chairman for the 2013 European Cancer Congress ECCO-ESMO-ESTRO and founding societies Multidisciplinary Cancer Congress. Most recently, she was the Genitourinary Cancer Track Leader of the Scientific Program Committee for the 2014 ASCO meeting, and has served a 3-year term on this Committee ending in 2016. Dr. Sternberg has also been an International Scientific Advisory Board (ISAB) Member of the Istituto Toscano Tumori (ITT). She has recently been elected to the ASCO Nominating Committee for a 3 year term and will be the Chair of the Committee from 2019 to 2020.
Dr. Sternberg was awarded the Grande Ufficiale al Merito della Repubblica Italiana in 2005 an has received the Premio Minerva for Scientific Achievement, XVIII Edition for Achievements in Science. Dr. Sternberg has also received the Premio ROSA Risultati Ottenuti Senza Aiuti Award for Special Achievement from the Canova Club in 2011. In 2013 she received the prestigious ESMO award for scientific achievement.
Dr Sternberg is the principal investigator for numerous studies, has published extensively > 350 articles in the fields of bladder, renal, and prostate cancer, lectured extensively and, is an associate editor and editorial board member of several international journals, and has co-edited several genitourinary oncology textbooks.
Dr Chris Sweeney Dr - Dana-Farber Cancer Institute, United States
Proudly sponsored by
Dr Sweeney graduated from the University of Adelaide in 1993 and is a Medical Oncologist at the Dana-Farber Cancer Institute and an Associate Professor at Harvard Medical School. His academic focus is on the management of genitourinary malignancies, with a special interest in management of advanced prostate and testicular cancer.